ARCHIVES

IDMC Halts Mekinist-Tafinlar Trial Early Due to OS Benefit; Recommends Crossover

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

Are Lab Budgets Excessive? Views On Intramural Program

April 21, 1995

Cancer Control Program Guidelines Developed For Payment Of Patient Costs

December 21, 1973

FDA Hazleton Probe Finds Some Problems; Results Unaffected

April 23, 1976

Only 20 Percent Of At-Risk Patients Are Screened For HBV Before Therapy

November 25, 2011

Triple-Negative Breast Cancer Increases With Number of Births

March 25, 2011

“Mind Boggling” Results Reported In Trials Using 3-Drug Combination For Breast Cancer

October 10, 1975